Jacobs Levy Equity Management
APRE icon

Jacobs Levy Equity Management’s Aprea Therapeutics APRE Stock Holding History

Jacobs Levy Equity Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,660
Closed -$272K – 967
2021
Q3 		$272K Sell
2,660
-5,174
-66% -$470K ﹤0.01% 952
2021
Q2 		$765K Sell
7,834
-2,184
-22% -$202K 0.01% 795
2021
Q1 		$1.02M Buy
+10,018
New +$1.17M 0.01% 731

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Jacobs Levy Equity Management's APRE Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Aprea Therapeutics (APRE) in Q4 2021, closing a stake of 2,660 shares — an estimated $272K sold.

Jacobs Levy Equity Management first reported a position in APRE in Q1 2021 and held it in 3 quarters. The position peaked at $1.02M in Q1 2021. 41 funds tracked by Wall St. Rank hold APRE as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Aprea Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,660 Aprea Therapeutics shares in Q4 2021, an estimated $272K.
  • Jacobs Levy Equity Management first reported a position in Aprea Therapeutics in Q1 2021 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Aprea Therapeutics position peaked at $1.02M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.